Search research articles
Contact Us
Filters
Showing results (41-50 of 45) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 45 results.
Frontiers in Oncology
|
November 17, 2022
Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer
Titto Augustine, Peter John, Tyler Friedman, et al.
BMC Cancer
|
June 5, 2026
The prognostic significance of B7-H3 expression in patients with advanced colorectal cancer
Yan Huang, Ana Acuna-Villaorduna, Radhika Gali, et al.
Clinical Colorectal Cancer
|
March 22, 2021
B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer
Wei Zhang, Ana Acuna-Villaorduna, Kevin Kuan, et al.
Investigational New Drugs
|
August 3, 2024
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Mohammad H Ghalib, Mariano Provencio Pulla, Maria J De Miguel Luken, et al.
Oncotarget
|
October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
Devika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 45) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 45 results.
Frontiers in Oncology
|
November 17, 2022
Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer
Titto Augustine, Peter John, Tyler Friedman, et al.
BMC Cancer
|
June 5, 2026
The prognostic significance of B7-H3 expression in patients with advanced colorectal cancer
Yan Huang, Ana Acuna-Villaorduna, Radhika Gali, et al.
Clinical Colorectal Cancer
|
March 22, 2021
B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer
Wei Zhang, Ana Acuna-Villaorduna, Kevin Kuan, et al.
Investigational New Drugs
|
August 3, 2024
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Mohammad H Ghalib, Mariano Provencio Pulla, Maria J De Miguel Luken, et al.
Oncotarget
|
October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
Devika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Page
of 5